Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 11/2016

01-11-2016 | Review

Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer

Authors: Fu Peng, Liang Xiong, Hailin Tang, Cheng Peng, Jianping Chen

Published in: Tumor Biology | Issue 11/2016

Login to get access

Abstract

Breast cancer is a malignant disease to treat among female worldwide due to its high capability to metastasize and mutate. Epithelial-mesenchymal transition is one of the essential processes involved in the metastatic capacity of breast cancer. In the recent time, the studies demonstrate that microRNAs, a kind of small non-coding RNA molecules, could be served as negative regulators in breast cancer, regulating cell cycle, drug resistance, and the process of metastasis in cancer development. With the assistance of microRNA profiling, the study concentrating on the regulatory function of miRNAs in breast cancer could be investigated more effectively and efficiently. More recent studies demonstrate that miRNAs have an important role to play in the EMT process of breast cancer to modulate metastasis. This small essay is on the purpose of demonstrating the significance and detection of miRNAs in breast cancer EMT process as oncogenes and tumor suppress genes through miRNA profiling according to the reports mainly in the recent 5 years, providing the evidence of efficient target therapy and effective pro-diagnosis focusing on miRNAs expression of breast cancer patients.
Literature
1.
2.
3.
4.
Reis-Filho JS et al. Metaplastic breast carcinomas are basal-like tumours. Histopathology. 2006;49(1):10–21.PubMedCrossRef
5.
Khoshnaw SM et al. MicroRNA involvement in the pathogenesis and management of breast cancer. J Clin Pathol. 2009;62(5):422–8.PubMedCrossRef
6.
7.
8.
Lee Y et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425(6956):415–9.PubMedCrossRef
9.
Hutvagner G et al. A cellular function for the RNA-interference enzyme dicer in the maturation of the let-7 small temporal RNA. Science. 2001;293(5531):834–8.PubMedCrossRef
10.
Silveri L et al. MicroRNA involvement in mammary gland development and breast cancer. Reprod Nutr Dev. 2006;46(5):549–56.PubMedCrossRef
11.
Cheng WC et al. YM500v2: a small RNA sequencing (smRNA-seq) database for human cancer miRNome research. Nucleic Acids Res. 2015;43(Database issue):D862–7.PubMedCrossRef
12.
13.
Iorio MV et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005;65(16):7065–70.PubMedCrossRef
14.
Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem. 2009;55(4):623–31.PubMedCrossRef
15.
16.
17.
Kaboli PJ et al. MicroRNA-based therapy and breast cancer: a comprehensive review of novel therapeutic strategies from diagnosis to treatment. Pharmacol Res. 2015;97:104–21.PubMedCrossRef
18.
19.
Su Y et al. Small molecule with big role: MicroRNAs in cancer metastatic microenvironments. Cancer Lett. 2014;344(2):147–56.PubMedCrossRef
20.
Lei R et al. Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis. Oncogene. 2014;33(10):1287–96.PubMedCrossRef
21.
Zhang, A.X., et al.. MicroRNA-217 overexpression induces drug resistance and invasion of breast cancer cells by targeting PTEN signaling. Cell Biol Int. 2015.
22.
23.
Han Q et al. MicroRNA-196a post-transcriptionally upregulates the UBE2C proto-oncogene and promotes cell proliferation in breast cancer. Oncol Rep. 2015;34(2):877–83.PubMed
24.
de Souza Rocha Simonini P et al. Epigenetically deregulated microRNA-375 is involved in a positive feedback loop with estrogen receptor alpha in breast cancer cells. Cancer Res. 2010;70(22):9175–84.PubMedCrossRef
25.
Zhao H et al. Genetic analysis and preliminary function study of miR-423 in breast cancer. Tumour Biol. 2015;36(6):4763–71.PubMedCrossRef
26.
Jin YY, Andrade J, Wickstrom E. Non-specific blocking of miR-17-5p guide strand in triple negative breast cancer cells by amplifying passenger strand activity. PLoS One. 2015;10(12):e0142574.PubMedPubMedCentralCrossRef
27.
Lu K et al. miRNA-24-3p promotes cell proliferation and inhibits apoptosis in human breast cancer by targeting p27Kip1. Oncol Rep. 2015;34(2):995–1002.PubMed
28.
Hu J et al. Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Tumour Biol. 2015;36(1):251–8.PubMedCrossRef
29.
30.
Xu XH et al. MiR-300 regulate the malignancy of breast cancer by targeting p53. Int J Clin Exp Med. 2015;8(5):6957–66.PubMedPubMedCentral
31.
Shi W et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 2011;71(8):2926–37.PubMedCrossRef
32.
Ortego M et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis. 1999;147(2):253–61.PubMedCrossRef
33.
34.
Huang S et al. miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor. PLoS One. 2013;8(12):e80707.PubMedPubMedCentralCrossRef
35.
Li Y et al. Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221. Tumour Biol. 2013;34(6):3545–54.PubMedCrossRef
36.
Nagpal N et al. MicroRNA-191, an estrogen-responsive microRNA, functions as an oncogenic regulator in human breast cancer. Carcinogenesis. 2013;34(8):1889–99.PubMedCrossRef
37.
Majumder S, Jacob ST. Emerging role of microRNAs in drug-resistant breast cancer. Gene Expr. 2011;15(3):141–51.PubMedCrossRef
38.
Ahmad A et al. Functional role of miR-10b in tamoxifen resistance of ER-positive breast cancer cells through down-regulation of HDAC4. BMC Cancer. 2015;15:540.PubMedPubMedCentralCrossRef
39.
Zhou, S., et al.. miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis. Tumour Biol. 2015.
40.
Huang X et al. miRNA-95 mediates radioresistance in tumors by targeting the sphingolipid phosphatase SGPP1. Cancer Res. 2013;73(23):6972–86.PubMedCrossRef
41.
Hu Q et al. MicroRNA-452 contributes to the docetaxel resistance of breast cancer cells. Tumour Biol. 2014;35(7):6327–34.PubMedCrossRef
42.
Su, C.M., et al.. miR-520 h is crucial for DAPK2 regulation and breast cancer progression. Oncogene. 2015.
43.
Tekiner TA, Basaga H. Role of microRNA deregulation in breast cancer cell chemoresistance and stemness. Curr Med Chem. 2013;20(27):3358–69.PubMedCrossRef
44.
Leal JA, Lleonart ME. MicroRNAs and cancer stem cells: therapeutic approaches and future perspectives. Cancer Lett. 2013;338(1):174–83.PubMedCrossRef
45.
Nandy SB et al. MicroRNA-125a influences breast cancer stem cells by targeting leukemia inhibitory factor receptor which regulates the hippo signaling pathway. Oncotarget. 2015;6(19):17366–78.PubMedPubMedCentralCrossRef
46.
Majumder M et al. COX-2 elevates oncogenic miR-526b in breast cancer by EP4 activation. Mol Cancer Res. 2015;13(6):1022–33.PubMedCrossRef
47.
De Cola A et al. miR-205-5p-mediated downregulation of ErbB/HER receptors in breast cancer stem cells results in targeted therapy resistance. Cell Death Dis. 2015;6:e1823.PubMedPubMedCentralCrossRef
48.
Iorio MV et al. MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer. 2008;44(18):2753–9.PubMedCrossRef
49.
Jin, C., et al.. Reciprocal regulation of Hsa-miR-1 and long noncoding RNA MALAT1 promotes triple-negative breast cancer development. Tumour Biol. 2015.
50.
51.
Tsouko E et al. miR-200a inhibits migration of triple-negative breast cancer cells through direct repression of the EPHA2 oncogene. Carcinogenesis. 2015;36(9):1051–60.PubMedCrossRef
52.
Liu T et al. MicroRNA-1 down-regulates proliferation and migration of breast cancer stem cells by inhibiting the Wnt/beta-catenin pathway. Oncotarget. 2015;6(39):41638–49.PubMedPubMedCentral
53.
Yang J et al. MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene. Oncogene. 2014;33(23):3014–23.PubMedCrossRef
54.
Yang S et al. MicroRNA-34 suppresses breast cancer invasion and metastasis by directly targeting Fra-1. Oncogene. 2013;32(36):4294–303.PubMedCrossRef
55.
Jiang, Q., et al.. MicroRNA-100 suppresses the migration and invasion of breast cancer cells by targeting FZD-8 and inhibiting Wnt/beta-catenin signaling pathway. Tumour Biol. 2015.
56.
Xue, J., et al.. MicroRNA-148a inhibits migration of breast cancer cells by targeting MMP-13. Tumour Biol, 2015.
57.
Li Y et al. miR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14. Cancer Res. 2015;75(13):2674–85.PubMedPubMedCentralCrossRef
58.
59.
60.
Patel JB et al. Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22. Oncogene. 2011;30(11):1290–301.PubMedCrossRef
61.
62.
Wang X et al. MicroRNA-99a inhibits tumor aggressive phenotypes through regulating HOXA1 in breast cancer cells. Oncotarget. 2015;6(32):32737–47.PubMedPubMedCentral
63.
Li W et al. MicroRNA-124 inhibits cellular proliferation and invasion by targeting Ets-1 in breast cancer. Tumour Biol. 2014;35(11):10897–904.PubMedCrossRef
64.
65.
Pan Y et al. MicroRNA-130a inhibits cell proliferation, invasion and migration in human breast cancer by targeting the RAB5A. Int J Clin Exp Pathol. 2015;8(1):384–93.PubMedPubMedCentral
66.
Schwickert A et al. microRNA miR-142-3p inhibits breast cancer cell invasiveness by synchronous targeting of WASL, integrin alpha V, and additional cytoskeletal elements. PLoS One. 2015;10(12):e0143993.PubMedPubMedCentralCrossRef
67.
68.
Phua YW et al. MicroRNA profiling of the pubertal mouse mammary gland identifies miR-184 as a candidate breast tumour suppressor gene. Breast Cancer Res. 2015;17:83.PubMedPubMedCentralCrossRef
69.
Cizeron-Clairac G et al. MiR-190b, the highest up-regulated miRNA in ERalpha-positive compared to ERalpha-negative breast tumors, a new biomarker in breast cancers? BMC Cancer. 2015;15:499.PubMedPubMedCentralCrossRef
70.
71.
Song GQ, Zhao Y. MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells’ growth and migration. Tumour Biol. 2015;36(7):5001–9.PubMedCrossRef
72.
Keklikoglou I et al. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene. 2012;31(37):4150–63.PubMedCrossRef
73.
74.
Mobarra N et al. Overexpression of microRNA-16 declines cellular growth, proliferation and induces apoptosis in human breast cancer cells. In Vitro Cell Dev Biol Anim. 2015;51(6):604–11.PubMedCrossRef
75.
Zheng T et al. CXCR4 3’UTR functions as a ceRNA in promoting metastasis, proliferation and survival of MCF-7 cells by regulating miR-146a activity. Eur J Cell Biol. 2015;94(10):458–69.PubMedCrossRef
76.
Kumaraswamy E et al. BRCA1 regulation of epidermal growth factor receptor (EGFR) expression in human breast cancer cells involves microRNA-146a and is critical for its tumor suppressor function. Oncogene. 2015;34(33):4333–46.PubMedCrossRef
77.
Ren Y et al. microRNA-200c downregulates XIAP expression to suppress proliferation and promote apoptosis of triple-negative breast cancer cells. Mol Med Rep. 2014;10(1):315–21.PubMed
78.
Qin L et al. Special suppressive role of miR-29b in HER2-positive breast cancer cells by targeting Stat3. Am J Transl Res. 2015;7(5):878–90.PubMedPubMedCentral
79.
80.
81.
Zhang Y et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res. 2011;71(10):3552–62.PubMedCrossRef
82.
Long J et al. MiR-503 inhibited cell proliferation of human breast cancer cells by suppressing CCND1 expression. Tumour Biol. 2015;36(11):8697–702.PubMedCrossRef
83.
Wang L et al. Downregulated miR-495 [corrected] inhibits the G1-S phase transition by targeting Bmi-1 in breast cancer. Medicine (Baltimore). 2015;94(21):e718.CrossRef
84.
85.
86.
Shukla K et al. MicroRNA-30c-2-3p negatively regulates NF-kappaB signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. Mol Oncol. 2015;9(6):1106–19.PubMedCrossRef
87.
Hargraves, K.G., L. He, and G.L. Firestone. Phytochemical regulation of the tumor suppressive microRNA, miR-34a, by p53-dependent and independent responses in human breast cancer cells. Mol Carcinog. 2015.
88.
89.
Aakula A et al. MicroRNA-135b regulates ERalpha, AR and HIF1AN and affects breast and prostate cancer cell growth. Mol Oncol. 2015;9(7):1287–300.PubMedCrossRef
90.
Eedunuri VK et al. miR-137 targets p160 steroid receptor coactivators SRC1, SRC2, and SRC3 and inhibits cell proliferation. Mol Endocrinol. 2015;29(8):1170–83.PubMedPubMedCentralCrossRef
91.
Zhao Y et al. MiR-137 targets estrogen-related receptor alpha and impairs the proliferative and migratory capacity of breast cancer cells. PLoS One. 2012;7(6):e39102.PubMedPubMedCentralCrossRef
92.
Hua W et al. MicroRNA-139 suppresses proliferation in luminal type breast cancer cells by targeting topoisomerase II alpha. Biochem Biophys Res Commun. 2015;463(4):1077–83.PubMedCrossRef
93.
Abedi N et al. miR-141 as potential suppressor of beta-catenin in breast cancer. Tumour Biol. 2015;36(12):9895–901.PubMedCrossRef
94.
95.
Wang X et al. MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway. Int J Clin Exp Pathol. 2015;8(5):5017–25.PubMedPubMedCentral
96.
Ge X et al. Overexpression of miR-206 suppresses glycolysis, proliferation and migration in breast cancer cells via PFKFB3 targeting. Biochem Biophys Res Commun. 2015;463(4):1115–21.PubMedCrossRef
97.
98.
Bai Y et al. MiR-615 inhibited cell proliferation and cell cycle of human breast cancer cells by suppressing of AKT2 expression. Int J Clin Exp Med. 2015;8(3):3801–8.PubMedPubMedCentral
99.
Endo Y et al. Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer. BMC Cancer. 2014;14:990.PubMedPubMedCentralCrossRef
100.
101.
102.
Adams, B.D., et al.. miR-34a Silences c-SRC to attenuate tumor growth in triple negative breast cancer. Cancer Res. 2015.
103.
Liu X et al. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer. Oncotarget. 2015;6(24):20070–83.PubMedPubMedCentralCrossRef
104.
Yuan Y et al. MiR-133a is functionally involved in doxorubicin-resistance in breast cancer cells MCF-7 via its regulation of the expression of uncoupling protein 2. PLoS One. 2015;10(6):e0129843.PubMedPubMedCentralCrossRef
105.
106.
He X et al. MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1. Tumour Biol. 2015;36(3):2065–75.PubMedCrossRef
107.
Demirkan B. The roles of epithelial-to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in breast cancer bone metastasis: potential targets for prevention and treatment. J Clin Med. 2013;2(4):264–82.PubMedPubMedCentralCrossRef
108.
109.
Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell. 2008;14(6):818–29.PubMedCrossRef
110.
Thiery JP, Sleeman JP. Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006;7(2):131–42.PubMedCrossRef
111.
Lacroix M. Significance, detection and markers of disseminated breast cancer cells. Endocr Relat Cancer. 2006;13(4):1033–67.PubMedCrossRef
112.
Drasin DJ, Robin TP, Ford HL. Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity. Breast Cancer Res. 2011;13(6):226.PubMedPubMedCentralCrossRef
113.
114.
D’Amato NC, Howe EN. J.K. Richer, MicroRNA regulation of epithelial plasticity in cancer. Cancer Lett. 2013;341(1):46–55.PubMedCrossRef
115.
Tang J et al. Molecular mechanisms of microRNAs in regulating epithelial-mesenchymal transitions in human cancers. Cancer Lett. 2016;371(2):301–13.PubMedCrossRef
116.
De Mattos-Arruda L et al. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget. 2015;6(35):37269–80.PubMedPubMedCentral
117.
118.
Chen D et al. MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1alpha-TWIST signaling axis in breast cancer. Oncotarget. 2015;6(32):32701–12.PubMedPubMedCentral
119.
Wang JG et al. Influence of miR-373 on the invasion and migration of breast cancer and the expression level of target genes TXNIP. J Biol Regul Homeost Agents. 2015;29(2):367–72.PubMed
120.
121.
Vetter G et al. miR-661 expression in SNAI1-induced epithelial to mesenchymal transition contributes to breast cancer cell invasion by targeting Nectin-1 and StarD10 messengers. Oncogene. 2010;29(31):4436–48.PubMedPubMedCentralCrossRef
122.
Kong X et al. MicroRNA-7 inhibits epithelial-to-mesenchymal transition and metastasis of breast cancer cells via targeting FAK expression. PLoS One. 2012;7(8):e41523.PubMedPubMedCentralCrossRef
123.
Li, G., et al.. Tumor-suppressive microRNA-34a inhibits breast cancer cell migration and invasion via targeting oncogenic TPD52. Tumour Biol. 2015.
124.
125.
Rhodes LV et al. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer. Oncotarget. 2015;6(18):16638–52.PubMedPubMedCentralCrossRef
126.
Shen PF et al. MicroRNA-494-3p targets CXCR4 to suppress the proliferation, invasion, and migration of prostate cancer. Prostate. 2014;74(7):756–67.PubMedCrossRef
127.
Liz, J. and M. Esteller. lncRNAs and microRNAs with a role in cancer development. Biochim Biophys Acta. 2015.
128.
129.
130.
Plummer PN et al. MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res. 2013;73(1):341–52.PubMedCrossRef
131.
132.
Yuryev A. Gene expression profiling for targeted cancer treatment. Expert Opin Drug Discovery. 2015;10(1):91–9.CrossRef
Metadata
Title
Regulation of epithelial-mesenchymal transition through microRNAs: clinical and biological significance of microRNAs in breast cancer
Authors
Fu Peng
Liang Xiong
Hailin Tang
Cheng Peng
Jianping Chen
Publication date
01-11-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 11/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5334-1

Other articles of this Issue 11/2016

Tumor Biology 11/2016 Go to the issue

Original Article

U/G SNP rs111904020 in 3′UTR of STAT3 regulated by miR-214 promotes hepatocellular carcinoma development in Chinese population

Original Article

NTRK2 is an oncogene and associated with microRNA-22 regulation in human gastric cancer cell lines

Review

Genotypic distribution of single nucleotide polymorphisms in oral cancer: global scene

Original Article

Overexpression of LARP1 predicts poor prognosis of colorectal cancer and is expected to be a potential therapeutic target

Original Article

Hypoxia-induced NIPP1 activation enhances metastatic potential and predicts poor prognosis in hepatocellular carcinoma

Original Article

TRPM7 channel inhibition mediates midazolam-induced proliferation loss in human malignant glioma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits